- Home
- VTYX vs VOXR Comparison
VTYX vs VOXR Comparison
Compare VTYX & VOXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- VOXR
- Stock Information
- Founded
- VTYX 2018
- VOXR 2014
- Country
- VTYX United States
- VOXR Canada
- Employees
- VTYX N/A
- VOXR N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- VOXR Precious Metals
- Sector
- VTYX Health Care
- VOXR Basic Materials
- Exchange
- VTYX Nasdaq
- VOXR Nasdaq
- Market Cap
- VTYX 154.9M
- VOXR 128.1M
- IPO Year
- VTYX 2021
- VOXR N/A
- Fundamental
- Price
- VTYX $1.61
- VOXR $2.38
- Analyst Decision
- VTYX Buy
- VOXR
- Analyst Count
- VTYX 4
- VOXR 0
- Target Price
- VTYX $11.33
- VOXR N/A
- AVG Volume (30 Days)
- VTYX 1.3M
- VOXR 123.4K
- Earning Date
- VTYX 03-04-2025
- VOXR 02-20-2025
- Dividend Yield
- VTYX N/A
- VOXR 1.68%
- EPS Growth
- VTYX N/A
- VOXR N/A
- EPS
- VTYX N/A
- VOXR N/A
- Revenue
- VTYX N/A
- VOXR $11,047,763.00
- Revenue This Year
- VTYX N/A
- VOXR N/A
- Revenue Next Year
- VTYX N/A
- VOXR $2.02
- P/E Ratio
- VTYX N/A
- VOXR N/A
- Revenue Growth
- VTYX N/A
- VOXR N/A
- 52 Week Low
- VTYX $1.57
- VOXR $1.81
- 52 Week High
- VTYX $11.48
- VOXR $3.24
- Technical
- Relative Strength Index (RSI)
- VTYX 34.49
- VOXR 46.10
- Support Level
- VTYX $1.57
- VOXR $2.45
- Resistance Level
- VTYX $1.78
- VOXR $2.63
- Average True Range (ATR)
- VTYX 0.10
- VOXR 0.13
- MACD
- VTYX -0.00
- VOXR 0.00
- Stochastic Oscillator
- VTYX 10.26
- VOXR 28.57
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of over 60 royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector.